查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1570791

同種異體幹細胞市場：按類型、細胞來源、應用和最終用戶分類 - 2025-2030 年全球預測

Allogeneic Stem Cells Market by Type (Cord Blood Transplant, Donor Lymphocyte Infusion, T-cell depleted Transplant), Cell Source (Adipose Tissue, Bone Marrow, Peripheral Blood Stem Cell), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年異體幹細胞市值為2.7834億美元，預計到2024年將達到3.2834億美元，複合年成長率為18.83%，到2030年將達到9.3134億美元。

同種異體幹細胞使用的細胞來自捐贈者，與取自患者體內的自體細胞不同。它在再生醫學中極為重要，可以治療血液疾病、免疫疾病、組織再生等。對同種異體幹細胞的需求源於其多功能，它為移植提供了可再生的細胞供應，並具有治療傳統治療方法難以治癒的疾病的潛力。其應用涵蓋腫瘤學、心血管學和神經學，主要最終用戶為醫院、研究機構和生物製藥公司。市場成長受到慢性病日益流行、細胞治療方法的進步以及鼓勵創新的法律規範的影響。新的商機包括快速發展的生物技術、增強的冷凍保存技術以及老齡化黃斑部病變等新治療領域的開拓。然而，免疫排斥、倫理問題、嚴格的法規和高成本等挑戰可能會阻礙進展。改善移植物抗宿主疾病的結果和開發多功能供體細胞的研究對於克服這些限制至關重要。該市場的特點是技術快速進步，重點是個人化醫療以及科學和商業領域的合作研究。創新領域包括使用基因編輯技術來提高幹細胞的功效、組織工程3D生物列印的進步以及整合人工智慧來最佳化細胞處理。由於該細分市場充滿活力，因此鼓勵公司投資於堅實的研發、建立策略夥伴關係並優先考慮監管協調。也應該專注於擴大臨床試驗網路和病患教育。積極主動地解決道德問題和開發大規模生產基礎設施將有助於市場進入。最終，創造一個促進創新和跨學科對話的環境將是同種異體幹細胞市場成功的關鍵。

主要市場統計
基準年[2023] 27834萬美元
預測年份 [2024] 3.2834億美元
預測年份 [2030] 93134萬美元
複合年成長率（%） 18.83%

市場動態：揭示快速發展的同種異體幹細胞市場的關鍵市場洞察

供需的動態交互作用正在改變同種異體幹細胞市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，以及消費行為如何影響製造成本，還可以更清楚地了解其對採購趨勢的影響。

波特五力：駕馭同種異體幹細胞市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解異體幹細胞市場的外部影響

外部宏觀環境因素在塑造同種異體幹細胞市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解異體幹細胞市場的競爭狀況

同種異體幹細胞市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣同種異體幹細胞市場供應商績效評估

FPNV定位矩陣是評估異體幹細胞市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪同種異體幹細胞市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，同種異體幹細胞市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告提供了涵蓋主要焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細審查，包括行業主要企業的廣泛資料、市場覆蓋範圍和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有產業的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢視市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病和退化性疾病盛行率增加
      • 消費者對個人化醫療的偏好日益成長
      • 擴大幹細胞研究和開發活動
    • 抑制因素
      • 開發同種異體幹細胞療法相關的高成本
    • 機會
      • 擴大聯合開發計劃的策略合作與夥伴關係
      • 有利的政府措施和增加的私人資金
    • 任務
      • 嚴格的法規遵從性和製造流程的複雜性
  • 市場區隔分析
    • 類型：將臍帶血移植系統擴展到兒科患者
    • 最終用戶：生物技術和製藥公司在幹細胞療法開發中擴大使用同種異體幹細胞
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章同種異體幹細胞市場：依類型

  • 介紹
  • 臍帶血移植
  • 供體淋巴細胞輸注
  • T細胞消融移植
  • 未經修飾的幹細胞移植

第7章同種異體幹細胞市場：依細胞來源分類

  • 介紹
  • 脂肪組織
  • 骨髓
  • 周邊血幹細胞
  • 臍帶血

第8章同種異體幹細胞市場：依應用分類

  • 介紹
  • 自體免疫疾病
  • 心血管疾病
  • 肌肉骨骼疾病
  • 腫瘤學

第9章同種異體幹細胞市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 生物技術和製藥公司
  • 醫院/診所
  • 幹細胞庫

第10章美洲同種異體幹細胞市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太同種異體幹細胞市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲同種異體幹細胞市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • VetStem Inc. 推出 PrecisePRP Canine，這是一種具有先進優勢的創新獸醫 PRP 治療方法
    • Cartherics 和 TiCARos 合作，透過結合創新的 CLIP-CAR 和 NK 細胞平台來推進癌症治療研究和商業化
    • Selecta Biosciences 和 Cartesian Therapeutics 聯手，憑藉強大的產品線和大量資金，推進針對自體免疫疾病的 RNA 細胞療法
  • 戰略分析和建議
Product Code: MRR-4969A8FF998A

The Allogeneic Stem Cells Market was valued at USD 278.34 million in 2023, expected to reach USD 328.34 million in 2024, and is projected to grow at a CAGR of 18.83%, to USD 931.34 million by 2030.

Allogeneic stem cells involve the use of donor-derived cells, distinct from autologous cells, sourced from the patient's body. They are pivotal in regenerative medicine, enabling treatments for hematological diseases, immune disorders, and tissue regeneration. The necessity of allogeneic stem cells arises from their potential to treat conditions unmanageable by conventional therapies, providing a renewable supply of cells for transplantation due to their pluripotent nature. Their applications span oncology, cardiovascular, and neurology, with hospitals, research institutes, and biopharmaceutical companies being key end-users. The market growth is influenced by the increasing prevalence of chronic diseases, advancements in cell-based therapies, and supportive regulatory frameworks that encourage innovation. Emerging opportunities include burgeoning biotechnologies, enhanced cryopreservation techniques, and the exploration of new therapeutic areas like age-related macular degeneration. However, challenges such as immunorejection, ethical concerns, stringent regulations, and high costs can impede progress. Research into improving graft-versus-host disease outcomes and developing universal donor cells is essential for overcoming these limitations. The market is characterized by rapid technological advancements, with a focus on personalized medicine and collaborations across scientific and commercial sectors. Innovative areas include the use of gene-editing techniques to enhance stem cell efficacy, advancements in 3D bioprinting for tissue engineering, and the integration of artificial intelligence to optimize cell processing. As the sector is highly dynamic, businesses are recommended to invest in robust R&D, forge strategic partnerships, and prioritize regulatory alignment. The emphasis should also be on expanding clinical trial networks and patient education. A proactive approach in addressing ethical concerns and improving the infrastructure for large-scale production will catalyze market engagement. Ultimately, fostering an environment conducive to innovation and cross-disciplinary dialogue will be key to navigating the allogeneic stem cell market successfully.

KEY MARKET STATISTICS
Base Year [2023] USD 278.34 million
Estimated Year [2024] USD 328.34 million
Forecast Year [2030] USD 931.34 million
CAGR (%) 18.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allogeneic Stem Cells Market

The Allogeneic Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic and degenerative diseases
    • Rising consumer preference for personalized medicine
    • Growing research and development activity in stem cells
  • Market Restraints
    • High costs associated with development of allogeneic stem cell therapies
  • Market Opportunities
    • Increasing strategic collaborations and partnerships for co-development projects
    • Favorable government initiatives and increasing private fundings
  • Market Challenges
    • Stringent regulatory compliance and complexities in manufacturing processes

Porter's Five Forces: A Strategic Tool for Navigating the Allogeneic Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allogeneic Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allogeneic Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allogeneic Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allogeneic Stem Cells Market

A detailed market share analysis in the Allogeneic Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allogeneic Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allogeneic Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allogeneic Stem Cells Market

A strategic analysis of the Allogeneic Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AgeX Therapeutics, Athersys, Inc., BioCardia, Inc., Bluebird Bio, Inc., BrainStorm Cell Therapeutics, Inc., Capricor Therapeutics, Inc, Cellectis SA, Celularity Inc., Fate Therapeutics, Inc., Gamida Cell Ltd., Helocyte, Inc., Hope Biosciences, LLC, ImmunityBio, Inc., JCR Pharmaceuticals Co., Ltd., Kadimastem Ltd., Lineage Cell Therapeutics, Inc., Lisata Therapeutics Inc., Mesoblast Limited, Pharmicell Co., Ltd., Pluristem Therapeutics Inc., ReNeuron Group plc, RoosterBio, Inc., SanBio, Inc., Sanofi S.A, Smith & Nephew plc, Stemedica Cell Technologies, Inc., Stempeutics Research Pvt Ltd, Vertex Pharmaceuticals Incorporated, and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Allogeneic Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cord Blood Transplant, Donor Lymphocyte Infusion, T-cell depleted Transplant, and Unmodified Stem Cell Transplant.
  • Based on Cell Source, market is studied across Adipose Tissue, Bone Marrow, Peripheral Blood Stem Cell, and Umbilical Cord Blood.
  • Based on Application, market is studied across Autoimmune Disease, Cardiovascular Disease, Musculoskeletal Disease, and Oncology.
  • Based on End-User, market is studied across Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Stem Cell Banks.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic and degenerative diseases
      • 5.1.1.2. Rising consumer preference for personalized medicine
      • 5.1.1.3. Growing research and development activity in stem cells
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with development of allogeneic stem cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing strategic collaborations and partnerships for co-development projects
      • 5.1.3.2. Favorable government initiatives and increasing private fundings
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance and complexities in manufacturing processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of cord blood transplant system for pediatric patients
    • 5.2.2. End-users: Rising usage of allogeneic stem cells in biotechnology and pharmaceutical companies for development of stem cell therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allogeneic Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Cord Blood Transplant
  • 6.3. Donor Lymphocyte Infusion
  • 6.4. T-cell depleted Transplant
  • 6.5. Unmodified Stem Cell Transplant

7. Allogeneic Stem Cells Market, by Cell Source

  • 7.1. Introduction
  • 7.2. Adipose Tissue
  • 7.3. Bone Marrow
  • 7.4. Peripheral Blood Stem Cell
  • 7.5. Umbilical Cord Blood

8. Allogeneic Stem Cells Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Disease
  • 8.3. Cardiovascular Disease
  • 8.4. Musculoskeletal Disease
  • 8.5. Oncology

9. Allogeneic Stem Cells Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Biotechnology & Pharmaceutical Companies
  • 9.4. Hospitals & Clinics
  • 9.5. Stem Cell Banks

10. Americas Allogeneic Stem Cells Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Allogeneic Stem Cells Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Allogeneic Stem Cells Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. VetStem Inc. launches PrecisePRP Canine, revolutionary veterinary PRP treatment with advance benefits
    • 13.3.2. Cartherics and TiCARos join forces combining innovative CLIP-CAR and NK cell platforms to advance cancer treatment research and commercialization
    • 13.3.3. Selecta Biosciences and Cartesian Therapeutics merge to advance RNA cell therapy for autoimmune diseases with a strong pipeline and substantial financial backing
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AgeX Therapeutics
  • 2. Athersys, Inc.
  • 3. BioCardia, Inc.
  • 4. Bluebird Bio, Inc.
  • 5. BrainStorm Cell Therapeutics, Inc.
  • 6. Capricor Therapeutics, Inc
  • 7. Cellectis SA
  • 8. Celularity Inc.
  • 9. Fate Therapeutics, Inc.
  • 10. Gamida Cell Ltd.
  • 11. Helocyte, Inc.
  • 12. Hope Biosciences, LLC
  • 13. ImmunityBio, Inc.
  • 14. JCR Pharmaceuticals Co., Ltd.
  • 15. Kadimastem Ltd.
  • 16. Lineage Cell Therapeutics, Inc.
  • 17. Lisata Therapeutics Inc.
  • 18. Mesoblast Limited
  • 19. Pharmicell Co., Ltd.
  • 20. Pluristem Therapeutics Inc.
  • 21. ReNeuron Group plc
  • 22. RoosterBio, Inc.
  • 23. SanBio, Inc.
  • 24. Sanofi S.A
  • 25. Smith & Nephew plc
  • 26. Stemedica Cell Technologies, Inc.
  • 27. Stempeutics Research Pvt Ltd
  • 28. Vertex Pharmaceuticals Incorporated
  • 29. Vita Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLOGENEIC STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CORD BLOOD TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DONOR LYMPHOCYTE INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY T-CELL DEPLETED TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UNMODIFIED STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MUSCULOSKELETAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023